French drugmaker Valneva said on Wednesday it will conduct a trial about the use of its COVID-19 vaccine candidate VLA2001 as a booster jab following a mRNA vaccination or natural infection.

Summary. Valneva SE offers exposure to a robust travel vaccine portfolio that includes Ixiaro, Dukoral, and Ixchiq. Ixiaro generated roughly €94.1 million in 2024 and remains Valneva’s main ...

Valneva obtains exclusive worldwide license for LimmaTech’s S4V Shigella vaccine candidate and adds an attractive Phase 2 clinical asset to Valneva’s R&D pipeline LimmaTech to receive upfront ...

Saint Herblain (France), April 18, 2025 – Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today announced that during its regular meeting on April 16, the U.S ...

Among the adopted resolutions were the approval of the 2024 financial statements, delegations for the Board of Directors to increase Valneva’s share capital and/or issue financial instruments, the ...

Saint-Herblain (France), November 9, 2023 –Valneva SE (Nasdaq: VALN; Euronext Paris: VLA), a specialty vaccine company, today reported consolidated financial results for the first nine months of ...

Valneva SE is a French biotechnology company specializing in developing and commercializing vaccines. We expect approval of two attractive vaccine candidates targeting Chikungunya and Lyme disease ...

Valneva’s chief medical officer Juan Carlos Jaramillo said: “We reiterate our support for the precautionary measures that have been taken as well as our commitment to continue monitoring all ...

Shares of Valneva VALN have plunged 52.9% in the trailing 12 months compared with the industry’s 33.8% decline. This substantial decline was caused by the revision of the advance purchase ...

5 Valneva Receives Marketing Authorization in the UK for the World’s First Chikungunya Vaccine, IXCHIQ® - Valneva 6 Vaccines on the table as chikungunya outbreak intensifies in India - BlueDot ...